Antoni Ribas
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.01%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 348
- Cancer Immunotherapy and Biomarkers 205
- CAR-T cell therapy research 181
- Cutaneous Melanoma Detection and Management 50
-
- Melanoma and MAPK Pathways 197
- Co-authors
- Jedd D. Wolchok (32 shared papers)Siwen Hu‐Lieskovan (30 shared papers)Jennifer A. Wargo (7 shared papers)Padmanee Sharma (2 shared papers)Keith T. Flaherty (54 shared papers)Grant A. McArthur (59 shared papers)Georgina V. Long (80 shared papers)Jeffrey A. Sosman (40 shared papers)
- Journals
- Journal of Clinical Oncology (146 papers)Cancer Research (39 papers)Clinical Cancer Research (26 papers)Annals of Oncology (24 papers)Cancer Discovery (17 papers)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
Antoni Ribas
540 papers receiving 61.2k citations
Antoni Ribas's Hit Papers
Peers
Comparison fields: 5 of 166
- Oncology 34.5k
- Immunology 20.0k
- Cancer Research 5.4k
- Molecular Biology 25.1k
- Pulmonary and Respiratory Medicine 5.9k
Countries citing papers authored by Antoni Ribas
This map shows the geographic impact of Antoni Ribas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoni Ribas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoni Ribas more than expected).
Fields of papers citing papers by Antoni Ribas
This network shows the impact of papers produced by Antoni Ribas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoni Ribas. The network helps show where Antoni Ribas may publish in the future.
Co-authors
The 25 scholars most cited alongside Antoni Ribas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 554 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer immunotherapy using checkpoint blockade Hit paper breakdown → | 2018 | 4753 |
| 2 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy Hit paper breakdown → | 2017 | 3845 |
| 3 | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Hit paper breakdown → | 2010 | 2620 |
| 4 | IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade Hit paper breakdown → | 2017 | 2429 |
| 5 | Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Hit paper breakdown → | 2010 | 1953 |
| 6 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Hit paper breakdown → | 2010 | 1615 |
| 7 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1506 |
| 8 | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Hit paper breakdown → | 2012 | 1390 |
| 9 | Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression Hit paper breakdown → | 2017 | 1365 |
| 10 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy Hit paper breakdown → | 2017 | 1165 |
| 11 | Classifying Cancers Based on T-cell Infiltration and PD-L1 Hit paper breakdown → | 2015 | 1143 |
| 12 | Tumour-intrinsic resistance to immune checkpoint blockade Hit paper breakdown → | 2019 | 1085 |
| 13 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 911 |
| 14 | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Hit paper breakdown → | 2012 | 889 |
| 15 | Targeted agents and immunotherapies: optimizing outcomes in melanoma Hit paper breakdown → | 2017 | 884 |
| 16 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 788 |
| 17 | Combination cancer immunotherapies tailored to the tumour microenvironment Hit paper breakdown → | 2015 | 744 |
| 18 | Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Hit paper breakdown → | 2013 | 718 |
| 19 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 651 |
| 20 | Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Hit paper breakdown → | 2016 | 611 |
About Antoni Ribas
Antoni Ribas is a scholar working on Oncology, Molecular Biology, Immunology, Organic Chemistry and Computational Theory and Mathematics, having authored 554 papers that have together received 62.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (205 papers), Melanoma and MAPK Pathways (197 papers), CAR-T cell therapy research (181 papers), Immunotherapy and Immune Responses (151 papers), Cutaneous Melanoma Detection and Management (50 papers), Immune Cell Function and Interaction (41 papers), T-cell and B-cell Immunology (39 papers) and Computational Drug Discovery Methods (31 papers). The work is most often cited by research in Oncology (34.5k citations), Immunology (20.0k citations), Cancer Research (5.4k citations), Molecular Biology (25.1k citations) and Pulmonary and Respiratory Medicine (5.9k citations). Antoni Ribas has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Jedd D. Wolchok, Siwen Hu‐Lieskovan, Jennifer A. Wargo, Padmanee Sharma, Keith T. Flaherty, Grant A. McArthur, Georgina V. Long, Jeffrey A. Sosman, Anusha Kalbasi and Roger S. Lo. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Annals of Oncology and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.